Drug
Nizatidine
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | End Stage Renal Disease | 72 | 54.3 | 57.0 | signal |
| 2 | Chronic Kidney Disease | 264 | 47.8 | 57.7 | signal |
| 3 | Renal Injury | 59 | 27.3 | 28.3 | signal |
| 4 | Tubulointerstitial Nephritis | 31 | 22.9 | 23.4 | signal |
| 5 | Acute Kidney Injury | 161 | 14.6 | 16.3 | signal |
| 6 | Renal Failure | 135 | 14.0 | 15.3 | signal |
| 7 | Nephropathy | 9 | 13.3 | 13.4 | signal |
| 8 | Disseminated Intravascular Coagulation | 13 | 12.8 | 12.9 | signal |
| 9 | Renal Tubular Necrosis | 8 | 11.3 | 11.3 | signal |
| 10 | Circulatory Collapse | 13 | 10.5 | 10.6 | signal |
| 11 | Nephropathy Toxic | 8 | 9.9 | 10.0 | signal |
| 12 | Gastrooesophageal Reflux Disease | 56 | 9.7 | 10.0 | signal |
| 13 | Hiatus Hernia | 9 | 9.6 | 9.7 | signal |
| 14 | Neurotoxicity | 12 | 9.6 | 9.6 | signal |
| 15 | Small Intestinal Obstruction | 8 | 9.0 | 9.1 | signal |
| 16 | Eye Inflammation | 6 | 8.8 | 8.8 | signal |
| 17 | Sinus Bradycardia | 6 | 8.6 | 8.6 | signal |
| 18 | Glossodynia | 13 | 8.1 | 8.1 | signal |
| 19 | Hepatic Function Abnormal | 21 | 7.8 | 7.9 | signal |
| 20 | Diabetes Mellitus Inadequate Control | 10 | 7.8 | 7.9 | signal |
| 21 | Blood Lactate Dehydrogenase Increased | 9 | 7.8 | 7.9 | signal |
| 22 | Depressed Level Of Consciousness | 20 | 7.0 | 7.1 | signal |
| 23 | Inappropriate Antidiuretic Hormone Secretion | 5 | 6.8 | 6.8 | signal |
| 24 | Upper Gastrointestinal Haemorrhage | 8 | 6.6 | 6.6 | signal |
| 25 | Chromaturia | 10 | 6.1 | 6.2 | signal |
| 26 | Acute Myocardial Infarction | 13 | 6.1 | 6.1 | signal |
| 27 | Myocardial Ischaemia | 5 | 6.0 | 6.0 | signal |
| 28 | Interstitial Lung Disease | 21 | 6.0 | 6.1 | signal |
| 29 | International Normalised Ratio Increased | 12 | 5.8 | 5.8 | signal |
| 30 | Parkinsonism | 4 | 5.7 | 5.7 | signal |
| 31 | Cerebral Infarction | 10 | 5.7 | 5.7 | signal |
| 32 | Basal Cell Carcinoma | 6 | 5.3 | 5.3 | signal |
| 33 | Angina Pectoris | 11 | 5.3 | 5.3 | signal |
| 34 | Angioedema | 16 | 5.0 | 5.1 | signal |
| 35 | Pulmonary Arterial Hypertension | 5 | 4.8 | 4.8 | signal |
| 36 | Fluid Overload | 5 | 4.7 | 4.7 | signal |
| 37 | Colon Cancer | 5 | 4.6 | 4.6 | signal |
| 38 | Respiratory Depression | 4 | 4.5 | 4.5 | signal |
| 39 | Delusion | 5 | 4.5 | 4.5 | signal |
| 40 | Deformity | 3 | 4.4 | 4.4 | signal |
| 41 | Coronary Artery Occlusion | 4 | 4.0 | 4.0 | signal |
| 42 | Peritonitis | 6 | 4.0 | 4.0 | signal |
| 43 | Blood Glucose Fluctuation | 3 | 3.8 | 3.8 | no signal |
| 44 | Sexual Dysfunction | 3 | 3.6 | 3.6 | no signal |
| 45 | Hallucination, Auditory | 4 | 3.5 | 3.5 | signal |
| 46 | Pancreatic Carcinoma | 7 | 3.3 | 3.3 | signal |
| 47 | Extrapyramidal Disorder | 6 | 3.3 | 3.3 | signal |
| 48 | Anorexia | 3 | 3.2 | 3.2 | no signal |
| 49 | Pharmaceutical Product Complaint | 6 | 3.2 | 3.2 | signal |
| 50 | Product Substitution Issue | 11 | 2.6 | 2.7 | signal |
| 51 | Palmar-plantar Erythrodysaesthesia Syndrome | 4 | 2.4 | 2.4 | no signal |
| 52 | Drug Effect Decreased | 9 | 2.3 | 2.3 | signal |
| 53 | Gastric Cancer | 4 | 2.2 | 2.2 | no signal |
| 54 | Tardive Dyskinesia | 3 | 1.5 | 1.5 | no signal |
| 55 | Oesophageal Carcinoma | 3 | 1.4 | 1.4 | no signal |
| 56 | Renal Cancer | 3 | 0.9 | 0.9 | no signal |